12 Jul 2019
Posted in Press Release
Abbott will gain an edge over competitors with FDA approval of Alinity™ s System
On 11th July 2019 Abbott announced that the U.S. Food and Drug Administration (FDA) has approved its Alinity™ s System, which can be used to screen whole blood and source plasma donations for infectious diseases such as HIV, Hepatitis B, and Hepatitis C.
Alison Casey, Medical Devices Analyst at GlobalData, a leading data and analytics company, offers her view:
“Abbott already commands a strong market share for many of these highly lucrative in vitro diagnostics (IVD) markets. Other manufacturers in this space include Bio-Rad Laboratories, Ortho-Clinical Diagnostics, Inc., Siemens Healthineers AG, and Roche Diagnostics International Ltd. The Alinity s System is expected to be more efficient than other competing systems, which will likely strength Abbott’s position in these infectious diseases IVD markets.
“GlobalData estimates that upwards of 151 million whole blood and source plasma donations were collected in 2018, with the majority being in the North American and Asia Pacific regions. These donations are screened for a number of different infectious diseases, meaning that they drive high volumes of sales for IVD reagents each year.”